Evaluating the long-term safety and effectiveness of the Dengvaxia vaccine in children in the Philippines
Official title: Long-term safety and effectiveness of Dengvaxia in the Philippines
Funded at University of Hawaii at Manoa · NIH-10946702 · Data updated 2026-11-12
This study is looking at how safe and effective the Dengvaxia vaccine is for children in the Philippines, especially those who may not have had dengue before getting the shot, to help us understand how well it works and any risks involved.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Hawaii at Manoa NIH-funded |
| Lab location | 1 site (Honolulu, United States) |
| Project start | August 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $615,068 |
| NIH project number | 1R01AI186073-01 |
| Project ID | NIH-10946702 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years who received the Dengvaxia vaccine in the Philippines.
✕Less likely to help
Patients who have not received the Dengvaxia vaccine or are outside the age range of 0-11 years may not benefit from this research.
What this research studies
This research investigates the long-term safety and effectiveness of the Dengvaxia vaccine, which was administered to over 830,000 children in the Philippines without prior testing for dengue virus exposure. The study aims to understand the immune responses, including antibody and T-cell responses, in children who received the vaccine, particularly focusing on those who may have been seronegative at the time of vaccination. By analyzing real-world data and responses to dengue infections, the research seeks to fill critical knowledge gaps regarding the vaccine's performance and associated risks. The findings could help inform future vaccination strategies and guidelines.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccination strategies that enhance safety and effectiveness for children at risk of severe dengue disease.
How similar studies have gone: Previous studies have indicated challenges with the Dengvaxia vaccine, particularly among seronegative recipients, highlighting the need for this investigation.
Where this research is happening
-
University of Hawaii at Manoa
Honolulu, United States Active
Researchers
- Principal investigator: Wang, Wei-Kung — University of Hawaii at Manoa
- Study coordinator: Wang, Wei-Kung
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.